Metropolis Healthcare Ltd is one of the leading diagnostics companies in India, by revenue, as of March 31, 2018. Company has widespread presence across 18 states in India, as of March 31, 2018, with leadership position in west and south India (Source: Frost & Sullivan). Through their widespread operational network, company offer a comprehensive range of clinical laboratory tests and profiles, which are used for prediction, early detection, diagnostic screening, confirmation and/or monitoring of the disease.
Company also offers analytical and support services to clinical research organizations for their clinical research projects. During the financial year 2018, they conducted approximately 16.0 million tests from approximately 7.7 million patient visits.
According to Frost & Sullivan, the Indian diagnostics market was valued at approximately ₹ 596 billion in the financial year 2018, and is projected to grow to approximately ₹ 802 billion by financial year 2020, driven by favorable changes in demographics, improvements in health awareness, increased spend on preventive care and wellness, increase in medical tourists, increase in lifestyle-related ailments and rising penetration of insurance in India.
Metropolis Healthcare Limited IPO - Issue Details:
||Metropolis Healthcare Limited (View Report)
||100% Book Built Issue IPO
||Issue Opens: Apr 03, 2019
| Issue Closes: Apr 05, 2019
||Rs.877* - Rs.880^ per Equity Share
||Rs.1,200.18* Crores - Rs.1,204.29^ Crores
||Rs.2 per Equity Share
||17 Equity Shares and in multiples thereof
|Maximum Bid amount for Retail
||Rs. 2 Lakhs
||75% of the issue size (Rs.880.40* Crs - Rs.883.42^ Crs)
||15% of the issue size (Rs.176.08* Crs - Rs.176.68^ Crs)
|Retail Individual Bidders
||10% of the issue size (Rs.117.39* Crs - Rs.117.79^ Crs)
||3,00,000 Equity Shares (Rs.26.31* Crs - Rs.26.40^ Crs)
||NSE & BSE
||Link Intime India Pvt Ltd
|Book Running Lead Managers
||JM Financial, Credit Suisse, Goldman Sach, HDFC Bank, Kotak Mahindra Capital
* Lower Price Band; ^ Upper Price Band